ORGANOGENESIS

Organogenesis Inc. is a regenerative medicine company with the unique skill set to take complex, living therapies from research and development (R&D), through manufacturing, to successful commercialization to reach patients today. As a pioneer in the field of regenerative medicine, Organogenesis received the first FDA approval of a living, allogeneic, cell based product (Apligraf®, approved for the treatment of venous leg ulcers). Apligraf is now the leading regenerative medicine product in the world, with two FDA-approved indications. In 2012 we received an FDA approval for GINTUIT™, a living, human cell-based product that represents a new therapeutic class in dentistry.